Decreased Iron Overload And Oxidative Stress In Transfusion Dependent Patients With Myelodysplastic Syndromes (Mds) With The Oral Iron Chelator Deferiprone

Background: The majority of the patients with low risk myelodysplastic syndrome (MDS) become RBC-transfusion-dependent and thus symptoms resulting from iron overload and oxidative stress may develop. Yet, iron-chelation has not been part of the standard treatment for these patients. The purpose of this study was to assess the effect of deferiprone (L1), an iron chelator, on oxidative stress parameters in iron overloaded and blood dependent patients with low risk MDS.